What the $63 Billion AbbVie Allergan Deal Says About the Drug Industry: Brainstorm Health

Good afternoon, readers. Let’s parse the big news out of the health care acquisitions world–AbbVie announced on Tuesday that it will buy Allergan in a deal valued at about $63 billion, a 45% premium on Allergan’s most recent closing stock price. The proposed M&A will be one of the largest health care mergers of the […]

What AbbVie’s $63 Billion Deal to Buy Allergan Says About the Drug Industry

AbbVie announced on Tuesday that it will buy Allergan in a deal valued at about $63 billion, a 45% premium on Allergan’s most recent closing stock price. The proposed M&A will be one of the largest health care mergers of the year and bring together a portfolio that includes AbbVie’s Humira, the world’s best-selling drug, […]

Senator Calls Tying Drugmaker CEO Pay to High Drug Price ‘Problematic’

AbbVie CEO Richard Gonzalez found himself getting grilled by a Senate panel on Tuesday about executive compensation and the price of the blockbuster drug Humira. You’ve likely heard of it, as stumbling across television commercials for Humira is easy. Pharmaceutical manufacturer AbbVie, a 2013 spin-off from Abbott Laboratories keeps them running on a regular basis, […]